Navigation Links
Bradmer announces 2008 fourth quarter and fiscal year operational and financial results
Date:3/31/2009

TSX: BMR

TORONTO, March 31 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Corporation") announced its 2008 fourth quarter and fiscal year operational and financial results.

Operational Highlights

During the year ended December 31, 2008, the Company achieved the following steps for its multi-center Phase III trial of its lead drug Neuradiab(R), a treatment for glioblastoma multiforme (GBM), the most advanced form of brain cancer:

    -   Prepared and submitted the Company's drug manufacturing data package
        and clinical dossiers to the FDA;
    -   Initiated enrollment in the Phase III GLASS-ART clinical trial;
    -   Signed contracts with and activated an initial cohort of five U.S.
        clinical trial sites;
    -   Successfully released a second GMP drug substance batch for use in
        clinical trials and filed the related update with the FDA;
    -   Submitted new data from the previous Phase II trial indicating that
        the mean time to progression free survival was 77 weeks, which
        compares favorably with other published results in newly diagnosed
        GBM (Reardon et al.; 2008 Neuro-Oncology 10:845); and
    -   Sourced and validated commercial supplies of iodine-131 outside of
        the U.S. and Europe to prevent delays in raw material supply.

Subsequent to the financial year ended December 31, 2008, the Company commenced a strategic review of its operations, as more particularly described in press releases of the Company dated February 17, 2009 and March 5, 2009. Pursuant to the strategic review, the Company has closed its Phase III GLASS ART Trial to further patient enrollment due to unforeseen delays in site initiation and recruitment, the delayed ability to complete the 60 patient "run-in phase" in a timely manner, and the inability to raise further capital at this time.

The Company has been, and is continuing to evaluate strategic options.

"We have successfully transitioned Neuradiab from a Phase II compound with compelling results at a single site to a cGMP manufactured compound in a multi-center Phase III trial under a rigorous protocol. We focused specifically on reducing risk in the critical areas of manufacturing, regulatory and clinical operations," said Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer. "We have initiated enrollment of patients across multiple sites and demonstrated those sites are adhering to the protocol as designed. However, the delay we have experienced in the 60-patient run-in phase has placed significant pressure on our capital resources which necessitated the strategic review by the Board."

Financial Results

Amounts in US dollars, unless specified otherwise, and results expressed in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

For the year ended December 31, 2008, Bradmer recorded a net loss of $11,529,000 or $0.85 per common share, compared to a net loss of $9,436,000 or $0.87 per common share for the year ended December 31, 2007. The increased loss in 2008 was primarily related to planned research and development spending with regard to the Corporation's lead clinical program, Neuradiab, in preparation for the Phase III clinical trial, as well as the growth in Bradmer's administrative functions in anticipation of the clinical trial launch.

Research and development expenses totaled $8,327,000 in fiscal 2008, compared to $7,256,000 in fiscal 2007. The increase was primarily due to increased compensation costs for the larger clinical staff amounting for $1,004,000 compared to $311,000 for 2007. The expenses incurred in 2008 for drug manufacturing contracts amounted to $3,351,000 compared to $3,970,000 in 2007. Amounts expensed to clinical research organizations were $2,350,000 in 2008, compared to $2,620,000 in 2007. During 2007, Bradmer manufactured drug product and conducted considerable analytical work to prepare for the start of the clinical trial.

General and administrative expenses were $3,389,000 in 2008 compared to $2,796,000 in the prior year as a result of the recruitment of senior executives and additional administrative support. Compensation costs amounted to $1,237,000 in 2008 compared to $1,101,000 in 2007. The portion of stock-based compensation, a noncash item, included in general and administrative expenses was $320,000 for the year, as compared to $324,000 for 2007. The remaining $124,000 of stock-based compensation is included in research and development expenses compared to $24,000 in 2007. Recruitment fees of $210,000 were incurred to retain clinical and manufacturing staff, compared to $101,000 in 2007.

Interest income was $273,000 during fiscal 2008 compared to $577,000 in 2007, due to lower cash balances and significantly lower interest rates.

For the three-month period ended December 31, 2008, Bradmer recorded a net loss of $2,327,000, or $0.17 per common share. This compares to a net loss of $3,517,000, or $0.26 per common share for the three months ended December 31, 2007. During the fourth quarter of 2008, the Corporation focused on cost reduction opportunities in all areas of the business in response to the credit crisis and the downtown in the economy.

Research and development expenses for the fourth quarter of 2008 were $1,586,000, compared to $2,826,000 in the same period of 2007. The decrease was primarily due to reduced support costs from our clinical research organization (CRO), for our Phase III clinical development program. The expenses incurred in 2008 consisted primarily of CRO costs of $354,000 and drug manufacturing and related analytical costs of $685,000.

General and administrative expenses were $761,000 in the fourth quarter of 2008, compared to $873,000 in 2007. The portion of stock-based compensation, a noncash item, included in general and administrative expenses was $28,000 for the quarter, compared to $96,000 in the same period in 2007. The remaining $21,000 of stock-based compensation is included in research and development expenses.

Interest income was $45,000 for the fourth quarter compared to $174,000 in the same period of 2007. The reduction was due to lower cash balances in 2008 and the significant decline in interest rates over the past year.

As at December 31, 2008, Bradmer had available cash and cash equivalents of $8,245,000 as compared to $19,469,000 as at December 31, 2007. The decrease in cash was due to funds spent on production of Neuradiab, on site initiation and patient enrollment. The Company expects that cash on hand at December 31, 2008 will be sufficient to fund the wind down of operations through 2009. We will be reducing funding to the minimum level consistent with our obligations to continue to monitor the progress and safety of the patients enrolled in the trial.

As at December 31, 2008, there were 13,488,215 common shares issued and outstanding.

Additional information about the Company, including the MD&A and financial results may be found on SEDAR at www.sedar.com.

About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

Bradmer Pharmaceuticals' lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. Bradmer has initiated enrollment of primary GBM patients in a Phase III multi-center clinical trial of Neuradiab. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

    Financial results are included below:


    Bradmer Pharmaceuticals Inc.
    Balance Sheets
    US $
                                                   December 31,  December 31,
                                                          2008          2007
                                                   ------------  ------------
    Assets

    Current
      Cash and cash equivalents                    $ 8,245,455   $19,469,337
      Amounts receivable                                12,520       143,722
      Prepaid expenses and other assets                 27,158        24,029
                                                   ------------  ------------

                                                     8,285,133    19,637,088

    Patent rights                                      711,054       685,165
                                                   ------------  ------------

                                                   $ 8,996,187   $20,322,253
                                                   ------------  ------------
                                                   ------------  ------------
    Liabilities

    Current
      Accounts payable and accrued liabilities     $ 1,594,578   $ 1,835,492
                                                   ------------  ------------

    Shareholders' Equity

    Capital stock                                   31,026,728    31,026,728

    Warrants                                           881,488       881,488

    Contributed surplus                              1,158,886       714,981

    Deficit                                        (25,665,493)  (14,136,436)
                                                   ------------  ------------

                                                     7,401,609    18,486,761
                                                   ------------  ------------

                                                   $ 8,996,187   $20,322,253
                                                   --------------------------
                                                   --------------------------



    Bradmer Pharmaceuticals Inc.
    Statements of Operations and Deficit
    US $

                      Three Months  Three Months
                             Ended         Ended    Year Ended    Year Ended
                       December 31,  December 31,  December 31,  December 31,
                              2008          2007          2008          2007
                      ------------- ------------- ------------- -------------
    Expenses
      Research &
       development    $  1,585,762  $  2,826,417  $  8,326,958  $  7,255,600
      General &
       administrative      760,608       872,750     3,389,453     2,795,860
      Amortization of
       patent rights        16,022        14,500        61,571        51,769
      Foreign exchange
       loss/(gain)           9,920       (22,474)       24,352       (90,399)
                      ------------- ------------- ------------- -------------

                         2,372,312     3,691,193    11,802,334    10,012,830

    Interest income         45,178       174,163       273,277       577,235
                      ------------- ------------- ------------- -------------

    Net loss            (2,327,134)   (3,517,030) $(11,529,057)   (9,435,595)

    Deficit at
     beginning of
     period           $(23,338,359)  (10,619,406)  (14,136,436)   (4,700,841)
                      ------------- ------------- ------------- -------------
    Deficit at end
     of period        $(25,665,493) $(14,136,437) $(25,665,493)  (14,136,436)
                      ------------- ------------- ------------- -------------
                      ------------- ------------- ------------- -------------
    Basic and diluted
     net loss per
     share            $      (0.17) $      (0.26) $      (0.85) $      (0.87)
                      ------------- ------------- ------------- -------------
                      ------------- ------------- ------------- -------------
    Weighted average
     number of shares   13,488,215    13,515,172    13,488,215   $10,827,882
                      ------------- ------------- ------------- -------------
                      ------------- ------------- ------------- -------------



    Bradmer Pharmaceuticals Inc.
    Statements of Cash Flows
    US $

                      Three Months  Three Months
                             Ended         Ended    Year Ended    Year Ended
                       December 31,  December 31,  December 31,  December 31,
                              2008          2007          2008          2007
                      ------------- ------------- ------------- -------------
    Cash flows from
     operating activities
      Net loss for the
       period         $ (2,327,134) $ (3,517,030) $(11,529,057) $ (9,435,595)
      Add items not
       affecting cash
        Amortization
         of patents         16,022        14,500        61,571        51,769
        Stock-based
         compensation       49,338        37,495       443,905       348,412
                      ------------- ------------- ------------- -------------

                      $ (2,261,774)   (3,465,035)  (11,023,581)   (9,035,414)

      Changes in
       non-cash
       working capital
       items
        Amounts
         receivable         (7,961)       12,692       131,202       (66,637)
        Prepaid expenses
         and other
         assets             19,210        24,960        (3,129)      (13,397)
        Accounts
         payable and
         accrued
         liabilities      (731,553)    1,147,681      (240,914)      451,125
                      ------------- ------------- ------------- -------------

                        (2,982,078)   (2,279,702)  (11,136,422)   (8,664,323)
                      ------------- ------------- ------------- -------------

    Cash flows from
     investing activities
      Investment in
       patent rights       (19,374)      (50,709)      (87,460)     (267,117)
      Purchase of
       short-term
       investment                -             -   (10,000,000)            -
      Redemption of
       short-term
       Investment                -             -    10,000,000             -
                      ------------- ------------- ------------- -------------
                           (19,374)      (50,709)      (87,460)     (267,117)
                      ------------- ------------- ------------- -------------
    Cash flows from
     financing activities
      Issuance of
       capital stock,
       net of share
       issue costs               -             -             -    19,588,150
      Repurchase of
       shares from
       employee                  -          (800)            -          (800)
                      ------------- ------------- ------------- -------------

                                 -          (800)            -    19,587,350
                      ------------- ------------- ------------- -------------

    Increase/(decrease)
     in cash during the
     period             (3,001,452)   (2,331,211)  (11,223,882)   10,655,910

    Cash and cash
     equivalents at
     beginning of
     period             11,246,907    21,800,548    19,469,337     8,813,427
                      ------------- ------------- ------------- -------------

    Cash and cash
     equivalents at
     end of period    $  8,245,455  $ 19,469,337  $  8,245,455  $ 19,469,337
                      ------------- ------------- ------------- -------------
                      ------------- ------------- ------------- -------------


'/>"/>
SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bradmer implements cash conservation plan
2. Bradmer provides clinical trial update and announces evaluation of strategic alternatives
3. Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
4. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
5. Bradmer announces 2008 third quarter operational and financial results
6. Bradmer to present at Rodman & Renshaw Healthcare Conference
7. Bradmer receives FDA approval to proceed with Phase III clinical trial
8. Bradmer announces 2008 first quarter operational and financial results
9. Bradmer announces new additions to management team
10. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
11. Notice of Bradmer Pharmaceuticals Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
Breaking Medicine Technology: